Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Pembrolizumab

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT05585034Phase 1Completed

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Pembrolizumab1
  • Xmab8081

Active Sponsors

  • Xencor, Inc.1

Top Investigators

Related Conditions

  • Renal Cell Carcinoma Clear Cell1
  • Tnbc Triplenegative Breast Cancer1
  • Melanoma Excluding Uveal Melanoma1
  • Head And Neck Squamous Cell Carcinoma1
  • Colorectal Cancer1

Activity Timeline